Table 1 Patient characteristics
Characteristics | No. (%) | p Value | |||
|---|---|---|---|---|---|
Overall | Age < 70 | Age ≥ 70 | |||
Patients | 95 | 70 | 25 | ||
Sex | Male | 71 (74.7) | 52 (74.3) | 19 (76.0) | 1.000 |
Female | 24 (25.3) | 18 (25.7) | 6 (24.0) | ||
Smoke | Never | 63 (67.7) | 43 (63.2) | 20 (80.0) | 0.199 |
Current or Former | 30 (32.3) | 25 (36.8) | 5 (20.0) | ||
Alcohol | Never | 79 (84.9) | 59 (86.8) | 20 (80.0) | 0.630 |
Current or Former | 14 (15.1) | 9 (13.2) | 5 (20.0) | ||
Allergy | No | 87 (93.5) | 67 (98.5) | 20 (80.0) | 0.006 |
Yes | 6 (6.5) | 1 (1.5) | 5 (20.0) | ||
KPS | < 90 | 23 (24.2) | 18 (25.7) | 5 (20.0) | 0.738 |
≥ 90 | 71 (74.7) | 51 (72.9) | 20 (80.0) | ||
NA | 1(0.1) | 1(1.4) | 0(0.0) | ||
ACE27 | < 2 | 51 (53.7) | 41 (58.6) | 10 (40.0) | 0.172 |
≥ 2 | 44 (46.3) | 29 (41.4) | 15 (60.0) | ||
CCI | 0 | 75 (78.9) | 54 (77.1) | 21 (84.0) | 0.663 |
≥ 1 | 20 (21.1) | 16 (22.9) | 4 (16.0) | ||
ACCI | < 4 | 85 (89.5) | 62 (88.6) | 23 (92.0) | 0.920 |
≥ 4 | 10 (10.5) | 8 (11.4) | 2 (8.0) | ||
EBV DNA | Negative | 22 (23.1) | 16 (22.9) | 6 (24.0) | 1.000 |
Positive | 68 (71.6) | 50 (71.4) | 18 (72.0) | ||
NA | 5 (5.3) | 4 (5.7) | 1 (4.0) | ||
Histology | Keratinized squamous cancer | 3 (3.2) | 3 (4.3) | 0 (0.0) | 0.567 |
Differentiated non-keratinized | 2 (2.1) | 1 (1.4) | 1 (4.0) | ||
Undifferentiated non-keratinized | 89 (93.7) | 65 (92.9) | 24 (96.0) | ||
Unclassified | 1 (1.1) | 1 (1.4) | 0 (0.0) | ||
Location of metastases | Liver | 22 (23.2) | 13 (18.6) | 9 (36.0) | 0.134 |
Bone | 23 (24.2) | 18 (25.7) | 5 (20.0) | 0.764 | |
Lung | 16 (16.8) | 12 (17.1) | 4 (16.0) | 1.000 | |
Current disease stage | Local recurrent | 48 (50.5) | 38 (54.3) | 10 (40.0) | 0.382 |
Recurrent with metastatic | 22 (23.2) | 14 (20.0) | 8 (32.0) | ||
Primary metastatic | 25 (26.3) | 18 (25.7) | 7 (28.0) | ||
Prior chemotherapya | Yes | 76 (80.0) | 63 (90.0) | 13 (52.0) | < 0.001 |
Prior radiotherapy | Yes | 91 (95.8) | 70 (100.0) | 21 (84.0) | 0.004 |
Treatment line of ICI therapy | ≥2 | 28 (29.5) | 21 (30.0) | 7 (28.0) | 1.000 |
1 | 67 (70.5) | 49 (70.0) | 18 (72.0) | ||
ICI type | Systemic | 75 (78.9) | 56 (80.0) | 19 (76.0) | 0.031 |
Neoajuvant | 3 (3.2) | 0 (0.0) | 3 (12.0) | ||
Concurrent | 6 (6.3) | 6 (8.6) | 0 (0.0) | ||
Adjuvant | 3 (3.2) | 2 (2.9) | 1 (4.0) | ||
Others | 8 (8.4) | 6 (8.6) | 2 (8.0) | ||
ICI agents | Camrelizumab | 5 (5.3) | 4 (5.7) | 1 (4.0) | 0.289 |
Sintilimab | 11 (11.6) | 11 (15.7) | 0 (0.0) | ||
Tislelizumab | 16 (16.8) | 11 (15.7) | 5 (20.0) | ||
Toripalimab | 58 (61.1) | 41 (58.6) | 17 (68.0) | ||
Others | 5 (5.3) | 3 (4.3) | 2 (8.0) | ||
ICI cycles | < 4 | 37 (38.9) | 27 (38.6) | 10 (40.0) | 1.000 |
≥ 4 | 58 (61.1) | 43 (61.4) | 15 (60.0) | ||
ICI maintenance | No | 71 (74.7) | 54 (77.1) | 17 (68.0) | 0.525 |
Yes | 24 (25.3) | 16 (22.9) | 8 (32.0) | ||
Chemotherapy | No | 13 (13.7) | 10 (14.3) | 3 (12.0) | 1.000 |
Yes | 82 (86.3) | 60 (85.7) | 22 (88.0) | ||
Platinum − containing chemotherapy | No | 38 (40.0) | 26 (37.1) | 12 (48.0) | 0.476 |
Yes | 57 (60.0) | 44 (62.9) | 13 (52.0) | ||
Dose reduction chemotherapy | No | 53 (55.8) | 36 (51.4) | 17 (68.0) | 0.231 |
Yes | 42 (44.2) | 34 (48.6) | 8 (32.0) | ||
Target therapy | No | 77 (81.1) | 55 (78.6) | 22 (88.0) | 0.462 |
Yes | 18 (18.9) | 15 (21.4) | 3 (12.0) | ||
Local therapy | No | 75 (78.9) | 56 (80.0) | 19 (76.0) | 0.178 |
Yes | 20 (21.1) | 14 (20.0) | 6 (24.0) | ||